AzTrials
AzTrials

Articular Cartilage DefectsExtensionNCT01251588

Extension Study for Participants of MACI00206 Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the Knee

An observational study of Articular Cartilage Defects, run by Vericel Corporation at 14 sites in 7 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To examine the 5-year efficacy and safety of MACI implant, compared with arthroscopic microfracture, in participants who received study treatment in the SUMMIT study for treatment of symptomatic articular cartilage defects of the knee. Read more about this study

Who is it for?
Ages 18 to 55 years
Conditions the study is for
Articular Cartilage Defects
What is being tested?
autologous cultured chondrocytes on porcine collagen membrane and Microfracture
Type of treatment
Surgery or procedure
How many people
128 participants
Where
14 sitesin 7 countries
Study dates
Dec 2010to Mar 2015
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • No healthy volunteers
  • Adult

Study population: Randomized and received study treatment (MACI or microfracture) in the SUMMIT study.

Randomized and received study treatment (MACI or microfracture) in the SUMMIT study.

Trial locations and contacts

14 sites in 7 countries.

14 sites in 7 countries

France3 sites
  • Polyclinique Saint-Roch

    Montpellier, 34967

  • Clinique Maussins-Nollet

    Paris, 75019

  • Hôpital d'instruction des Armées Robert Picqué

    Villenave-d'Ornon, 33882

Other trials in France

Netherlands3 sites
  • Academisch Ziekenhuis Maastricht

    Maastricht, 6202 AZ

  • St. Elisabeth Ziekenhuis

    Tilburg, 5022 GC

  • University Medical Centre of Utrecht, Department of Orthopaedics

    Utrecht, 3508 GA

Other trials in Netherlands

Poland3 sites
  • Orthopaedic & Traumatology of Motor Organs, Independent Public Clinic Hospital

    Bydgoszcz, 85-094

  • Regional Centre of Knee Surgery & Arthroscopy, Regional Hospital of Traumatologic Surgery

    Piekary Śląskie, 41-940

  • Lekmed Medical Center

    Warszewo, 01-480

Other trials in Poland

Czechia2 sites
  • Urazova nemocnice v Brne

    Brno, 662 50

  • University Hospital Na Bulovce- Department of Orthopaedic Surgery Postgraduate Medical Institute

    Prague, 180 81

Other trials in Czechia

Norway1 site
  • St Olavs Hospital

    Trondheim, 7006

Other trials in Norway

Sweden1 site
  • Kungsbacka Närsjukhus

    Kungsbacka, 434 80

Other trials in Sweden

United Kingdom1 site
  • University of Oxford, Nuffield Dept. of Orthopaedic Surgery

    Oxford, OX3 7LD

Other trials in United Kingdom

About this study

Official title: An Extension Protocol for Participants of Genzyme-Sponsored Prospective, Randomized, Open-Label, Parallel-Group, Multicenter Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the Femoral Condyle Including the Trochlea

To examine the 5-year efficacy and safety of MACI implant, compared with arthroscopic microfracture, in participants who received study treatment in the SUMMIT study for treatment of symptomatic articular cartilage defects of the knee.

Read the detailed description

This study was an open-label, multicenter extension to the SUMMIT study designed to examine the 5-year efficacy and safety of MACI compared to arthroscopic microfracture in the treatment of articular cartilage defects of the knee in participants who received study treatment in the SUMMIT study. Follow-up to 2 years post-study treatment was completed as part of the SUMMIT study. Follow-up from 3 to 5 years post-study treatment in SUMMIT was completed in this extension study.

All 144 participants who received study treatment in the SUMMIT study were eligible for enrollment into this extension study. Participants had until the end of the visit window for the last visit of this extension study (ie, Week 260 + 6 weeks) to consent to enter this extension study.

Efficacy and safety assessments were performed at scheduled visits 3, 4, and 5 years following treatment in SUMMIT (ie, at Weeks 156, 208, and 260 postarthrotomy for patients treated with MACI implant or at Weeks 156, 208, and 260 postarthroscopy for patients treated with microfracture).

Being tested
autologous cultured chondrocytes on porcine collagen membrane, Microfracture
Keywords
Cartilage legions, Symptomatic focal cartilage defects, Microfracture, MACI, Autologous chondrocyte
Medical subject headings
Fractures, Stress

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • autologous cultured chondrocytes on porcine collagen membraneBiological

    Also called MACI, matrix applied characterized autologous cultured chondrocytes

    Implantation received in the previous MACI00206 study

  • MicrofractureProcedure or surgery

    Arthroscopic Microfracture treatment received in the previous MACI00206 study

Study groups in NCT01251588
Study groupRoleWhat they receive
MACIautologous cultured chondrocytes on porcine collagen membrane implant received in previous MACI00206 study
Receives: Biological: autologous cultured chondrocytes on porcine collagen membrane
MicrofractureMicrofracture treatment received in previous MACI00206 study
Receives: Procedure: Microfracture

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From MACI00206 Baseline for the Participant's Knee Injury and Osteoarthritis Outcome (KOOS) Pain and Function (Sports and Recreational Activities) Scores.

    The KOOS is a validated knee-specific instrument developed to assess the patients' opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL). A 5-point Likert scale was used to record the response to each item ranging from 0 (no problems) to 4 (extreme problems). Within each subscale, items were added up and normalized to a value between 0 (extreme problems) and 100 (no problems). Subscales are not combined to calculate a total score.

    Measured: MACI00206 Baseline to Week 156

Secondary outcomes (13)
  1. Change From MACI00206 Baseline for the Participant's KOOS Pain and Function (Sports and Recreational Activities) Scores

    The KOOS is a validated knee-specific instrument developed to assess the patients' opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL). A 5-point Likert scale was used to record the response to each item ranging from 0 (no problems) to 4 (extreme problems). Within each subscale, items were added up and normalized to a value between 0 (extreme problems) and 100 (no problems). Subscales are not combined to calculate a total score.

    Measured: MACI00206 Baseline and Week 260

  2. Magnetic Resonance Imaging (MRI) Assessments of Degree of Defect Fill

    MRI was assessed by the independent blinded evaluators by means of consensus. The number of participants with a degree of defect fill of >50% is reported.

    Measured: Week 260

  3. Proportion of Patients Who Achieve at Least a 10-point Improvement From MACI00206 Baseline in KOOS Pain and Function (Sports and Recreational Activities) Scores

    A responder is defined as a participant with at least a 10-point improvement in both the KOOS Pain and Function (Sports and Recreational activities) scores from MACI00206 Baseline scores.

    Measured: Up to week 260

  4. The Proportion of Patients in Each Treatment Group Assessed as Treatment Failures

    Patients were considered as a treatment failure if all of the following 5 criteria were met:

    1. Patient's global assessment of their knee joint compared to Baseline was the same or worse
    2. Physician's global assessment of the patient's knee joint compared to Baseline was the same, worse, or significantly worse.
    3. Percent improvement from Baseline in KOOS Pain score was less than 10%.
    4. Physician diagnostic evaluation of failure excluded etiologies (eg, meniscal tear) other than failed treatment of the index lesion.
    5. The physician decided that surgical re-treatment of the index lesion(s) was required that involved either extensive debridement for lesion expansion, violation of the subchondral bone, or ACI.

    Measured: Years 2 through 5 post treatment (MACI or microfracture)

  5. Average Time to Treatment Failure

    ANALYSIS NOT DONE: The planned analyses concerning time to treatment failure were not conducted due to the small number of per protocol treatment failure cases. The number of per protocol treatment failures in each treatment group are reported here.

    Patients were considered as a treatment failure if all of the following 5 criteria were met:

    1. Patient's global assessment of their knee joint compared to Baseline was the same or worse
    2. Physician's global assessment of the patient's knee joint compared to Baseline was the same, worse, or significantly worse.
    3. Percent improvement from Baseline in KOOS Pain score was less than 10%.
    4. Physician diagnostic evaluation of failure excluded etiologies (eg, meniscal tear) other than failed treatment of the index lesion.
    5. The physician decided that surgical re-treatment of the index lesion(s) was required that involved either extensive debridement for lesion expansion, violation of the subchondral bone, or ACI.

    Measured: Up to 260 weeks

  6. Change From MACI00206 Baseline in the Remaining 3 Subscales (Activities of Daily Living, Quality of Life, and Other Symptoms) of KOOS

    The KOOS is a validated knee-specific instrument developed to assess the patients' opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL). A 5-point Likert scale was used to record the response to each item ranging from 0 (no problems) to 4 (extreme problems). Within each subscale, items were added up and normalized to a value between 0 (extreme problems) and 100 (no problems). Subscales are not combined to calculate a total score.

    Measured: MACI00206 Baseline and Week 260

  7. Change From MACI00206 Baseline in the Patient's Evaluation of Overall Knee Condition Using the International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form

    The IKDC Subjective Knee Evaluation Form is a validated knee-specific measure of symptoms, function, and sports activity that is appropriate for patients with a wide variety of knee problems. The form consists of 18 items covering the domains of symptoms, functioning during activities of daily living and sports, and current function of the knee.

    The IKDC Subjective Knee Evaluation Form is scored by summing the scores for the individual items and then transforming the score to a scale that ranges from 0 to 100. The transformed score is interpreted as a measure of function such that higher scores represent higher levels of function and lower levels of symptoms. A score of 100 is interpreted to mean no limitation with activities of daily living or sports activities and the absence of symptoms.

    Measured: MACI00206 Baseline and Week 260

  8. Change From MACI00206 Baseline in the Patient's Evaluation of Overall Knee Condition Using the Modified Cincinnati Knee Rating System

    The Modified Cincinnati Knee Rating System is a self-assessment of the intensity of sports participation, functional limitations, and the ability to participate in different types of sports. The Modified Cincinnati Knee Rating System overall knee condition score ranges from 1 (poor) to 10 (excellent).

    Measured: MACI00206 Baseline and Week 260

  9. Change From MACI00206 Baseline in the 12-Item Short-Form Health Survey (SF-12) Physical and Mental Component Scores

    The SF-12 is a subset of the 36-Item Short-Form Health Survey (SF-36) and includes 8 subscales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) that are used to calculate the physical (PCS) and mental (MCS) summary component scores.

    MCS and PCS are summarized as Z-scores using standard SF-12 scoring and a US population means. The Z-score indicates how many standard deviations a score is from the population mean. Higher values reflect better health. Changes from Baseline are reported.

    Measured: MACI00206 Baseline and Week 260

  10. Change From MACI00206 Baseline in the European Quality of Life 5 Dimensions (EQ-5D) Visual Analog Scale (VAS) Score

    The EQ-5D is a standardized instrument for use as a measure of health outcome (see the EuroQOL Website for details: www.euroqol.org). Applicable to a wide range of health conditions and treatments, it provides a simple descriptive profile and a single index value for health status. The EQ Visual Analogue Scale (VAS) was used to record the respondents' self-rated health status on a vertical graduated (0-100) VAS where 0 is 'the worst health you can imagine' and 100 is 'the best health you can imagine'.

    Measured: MACI00206 Baseline and Week 260

  11. Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs)

    Measured: Years 2 through 5 post treatment (MACI or microfracture)

  12. Number of Participants Reporting Serious Adverse Events (SAEs)

    Measured: Years 2 through 5 post treatment (MACI or microfracture)

  13. Number of Participants Having Subsequent Surgical Procedures (SSPs) in Target Knee

    Measured: Years 2 through 5 post treatment (MACI or microfracture)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Dec 2010 (estimated)
  2. Study startDec 2010
  3. Primary completionMar 2015
  4. Study completionMar 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
128 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01251588
Sponsor's protocol ID
MACI00809
Other IDs
2009-016970-33, 2009
Acronym
Extension
Status last verified
May 2021
First submitted
30 Nov 2010
Last updated
12 May 2021
Data monitoring committee
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Articular Cartilage Defects, run by Vericel Corporation at 14 sites in 7 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 May 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 14 sites in France, Netherlands, Poland, Czechia, Norway and 2 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 27 Apr 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From MACI00206 Baseline for the Participant's Knee Injury and Osteoarthritis Outcome (KOOS) Pain and Function (Sports and Recreational Activities) Scores. (time frame: MACI00206 Baseline to Week 156). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in